- Home
- NERV vs INDP Comparison
NERV vs INDP Comparison
Compare NERV & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- INDP
- Stock Information
- Founded
- NERV 2007
- INDP 2000
- Country
- NERV United States
- INDP United States
- Employees
- NERV N/A
- INDP N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- INDP Health Care
- Exchange
- NERV Nasdaq
- INDP Nasdaq
- Market Cap
- NERV 10.7M
- INDP 8.8M
- IPO Year
- NERV 2014
- INDP N/A
- Fundamental
- Price
- NERV $1.61
- INDP $0.50
- Analyst Decision
- NERV Hold
- INDP Strong Buy
- Analyst Count
- NERV 1
- INDP 2
- Target Price
- NERV $5.00
- INDP $8.50
- AVG Volume (30 Days)
- NERV 15.1K
- INDP 1.2M
- Earning Date
- NERV 04-30-2025
- INDP 03-13-2025
- Dividend Yield
- NERV N/A
- INDP N/A
- EPS Growth
- NERV N/A
- INDP N/A
- EPS
- NERV 0.19
- INDP N/A
- Revenue
- NERV N/A
- INDP N/A
- Revenue This Year
- NERV N/A
- INDP N/A
- Revenue Next Year
- NERV N/A
- INDP N/A
- P/E Ratio
- NERV $8.95
- INDP N/A
- Revenue Growth
- NERV N/A
- INDP N/A
- 52 Week Low
- NERV $1.42
- INDP $0.47
- 52 Week High
- NERV $3.69
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- NERV 41.00
- INDP 24.26
- Support Level
- NERV $1.54
- INDP $0.58
- Resistance Level
- NERV $1.89
- INDP $0.78
- Average True Range (ATR)
- NERV 0.11
- INDP 0.14
- MACD
- NERV 0.00
- INDP -0.03
- Stochastic Oscillator
- NERV 22.68
- INDP 1.89
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.